Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930465 | 1.00 | ATM (0.54) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL5174853 | 0.94 | APP (0.55) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL28658552 | 0.91 | APP (0.51) | APPKDM4EALDH1A1HCAR2HPGD | |
| SCHEMBL29975450 | 0.90 | ATM (0.50) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL1897277 | 0.86 | CA12 (0.54) | ATMKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1897276 | 0.86 | CA12 (0.54) | ATMKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11834908 | 0.85 | APP (0.60) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL19244396 | 0.85 | KDM4E (0.61) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL3940920 | 0.85 | APP (0.60) | ATMAPPKDM4EALDH1A1HCAR2 | |
| SCHEMBL18843944 | 0.85 | ATM (0.54) | ATMAPPKDM4EALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909130-B1 | CATALYSIS BY METAL NANOPARTICLES DISPERSED WITHIN A HIERARCHICALLY POROUS CARBON MATERIAL | BAKKER MARTIN (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-103509562-B | Crystal aligning agent, liquid crystal orienting film, phase retardation film, the manufacture method of phase retardation film, liquid crystal display cells and polymer | JSR株式会社 | 2017-08-04 | — | — | CN | disclosed |
| US-9669388-B2 | Catalysis by metal nanoparticles dispersed within a hierarchically porous carbon material | The Board Trustees of The University of Alabama (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160089657-A1 | CATALYSIS BY METAL NANOPARTICLES DISPERSED WITHIN A HIERARCHICALLY POROUS CARBON MATERIAL | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2016-03-31 | — | — | US | disclosed |
| US-9233366-B2 | Catalysis by metal nanoparticles dispersed within a hierarchically porous carbon material | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140107371-A1 | CATALYSIS BY METAL NANOPARTICLES DISPERSED WITHIN A HIERARCHICALLY POROUS CARBON MATERIAL | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-04-17 | — | — | US | disclosed |
| US-5698755-A | Process for preparing aromatic olefins using palladacycle catalysis | HOECHST AG (DE) | 1997-12-16 | — | — | US | disclosed |
| EP-0301587-A1 | Liquid crystal compounds and intermediates thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0094432-A1 | LIQUID CRYSTAL DISPLAY UNIT | SONY CORPORATION (JP) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | ATM 3041/4885APP 2234/4885KDM4E 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.